Humoral Response to SARS-COV-2 Vaccination in Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Real-World Study.

ABSTRACT:

Introduction

The risk of SARS-CoV-2 infection or severe coronavirus disease 2019 (COVID-19) has been shown to increase in patients with multiple sclerosis (MS). Vaccination is recommended in this patient population, and the effect of disease-modifying treatments (DMTs) on response to vaccination should be considered.

Methods

This prospective, observational, cross-sectional study investigated humoral response after COVID-19 vaccination as well as possible predictors for response in patients with MS and other neuroinflammatory diseases who received DMTs in routine clinical practice in Spain. Responses were compared versus those seen in healthy controls.

Results

After vaccination against COVID-19, most patients with MS developed an immune response comparable to that of h

SUBMITTER: Millan-Pascual J 

PROVIDER: S-EPMC10787726 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature